{"id":"ifosfamide-for-injection","safety":{"commonSideEffects":[{"rate":"60–90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"5–40","effect":"Hemorrhagic cystitis"},{"rate":"60–90","effect":"Nausea and vomiting"},{"rate":"60–80","effect":"Alopecia"},{"rate":"10–15","effect":"CNS toxicity (encephalopathy, confusion)"},{"rate":"5–10","effect":"Nephrotoxicity"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":{"chemblId":"CHEMBL1024","moleculeType":"Small molecule","molecularWeight":"261.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ifosfamide is a nitrogen mustard derivative that requires hepatic activation to its active metabolite. Once activated, it forms covalent bonds between DNA strands (cross-linking), disrupting DNA replication and transcription. This leads to apoptosis in rapidly dividing cancer cells. It is cell-cycle nonspecific and has activity against a broad range of malignancies.","oneSentence":"Ifosfamide is an alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:29.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Germ cell testicular cancer"},{"name":"Lymphoma"},{"name":"Soft tissue sarcoma"},{"name":"Bone sarcoma"},{"name":"Cervical cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT05813327","phase":"PHASE1","title":"Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-03-14","conditions":"Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue","enrollment":6},{"nctId":"NCT04570423","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","status":"RECRUITING","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2021-05-20","conditions":"Solid Tumors, Lymphoma","enrollment":40},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT06277154","phase":"PHASE2","title":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"HRYZ Biotech Co.","startDate":"2024-02-21","conditions":"Leiomyosarcoma, Liposarcoma, Synovial Sarcoma","enrollment":148},{"nctId":"NCT06220097","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory","enrollment":28},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT06699472","phase":"PHASE2","title":"A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-31","conditions":"Ewing Sarcoma, Myelosuppression","enrollment":22},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT01026220","phase":"PHASE3","title":"Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2009-12-07","conditions":"Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma","enrollment":166},{"nctId":"NCT02732015","phase":"PHASE2","title":"Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-12","conditions":"Locally Advanced Sarcoma","enrollment":37},{"nctId":"NCT04342936","phase":"PHASE3","title":"Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-17","conditions":"Classical Hodgkin Lymphoma","enrollment":56},{"nctId":"NCT00864318","phase":"PHASE2","title":"Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2009-03-13","conditions":"Germ Cell Tumors","enrollment":101},{"nctId":"NCT04699214","phase":"PHASE2","title":"Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment","status":"UNKNOWN","sponsor":"Yong Chen","startDate":"2020-09-01","conditions":"Other Disorders of Soft Tissues","enrollment":210},{"nctId":"NCT02544425","phase":"PHASE2","title":"VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2016-02-21","conditions":"Extranodal NK-T-Cell Lymphoma","enrollment":27},{"nctId":"NCT03121833","phase":"PHASE2","title":"Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2017-05-01","conditions":"Soft Tissue Sarcoma, Adult, Stage IIB","enrollment":52},{"nctId":"NCT03815474","phase":"PHASE2","title":"Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients","status":"UNKNOWN","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2019-05-20","conditions":"Sarcoma, Soft Tissue","enrollment":47},{"nctId":"NCT01966913","phase":"PHASE1, PHASE2","title":"Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Germ Cell Tumor","enrollment":30},{"nctId":"NCT00623077","phase":"PHASE1","title":"MT2004-30: Tomotherapy for Solid Tumors","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08","conditions":"Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer","enrollment":23},{"nctId":"NCT00003597","phase":"PHASE1","title":"Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1998-11","conditions":"Cancer","enrollment":16},{"nctId":"NCT00147225","phase":"PHASE1, PHASE2","title":"AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08","conditions":"Solid Tumors, Advanced Cancer","enrollment":55},{"nctId":"NCT00499343","phase":"PHASE2","title":"G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-01","conditions":"Lymphoma","enrollment":84},{"nctId":"NCT00006708","phase":"PHASE3","title":"S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2000-10","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT00696735","phase":"PHASE3","title":"High-Dose Therapy Treatment in Patients With Follicular Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1994-06","conditions":"Follicular Lymphoma","enrollment":172}],"_emaApprovals":[],"_faersSignals":[{"count":89,"reaction":"FEBRILE NEUTROPENIA"},{"count":19,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":16,"reaction":"DISEASE PROGRESSION"},{"count":15,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":13,"reaction":"RESPIRATORY FAILURE"},{"count":12,"reaction":"ENCEPHALOPATHY"},{"count":12,"reaction":"SEPSIS"},{"count":11,"reaction":"MUCOSAL INFLAMMATION"},{"count":10,"reaction":"PYREXIA"},{"count":9,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NSC109724"],"phase":"phase_3","status":"active","brandName":"Ifosfamide for Injection","genericName":"Ifosfamide for Injection","companyName":"BeBetter Med Inc","companyId":"bebetter-med-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ifosfamide is an alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death. Used for Germ cell testicular cancer, Lymphoma, Soft tissue sarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}